Cargando…
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
Patients with metastatic colorectal cancer (mCRC) are routinely screened for either K- and N-RAS to select the appropriate treatment. The present study aimed to evaluate the concordance between K- and NRAS status in the tissue (either primary tumor or metastasis) and the plasma of patients with mCRC...
Autores principales: | Lastraioli, Elena, Antonuzzo, Lorenzo, Fantechi, Beatrice, Di Cerbo, Luisa, Di Costanzo, Alessandro, Lavacchi, Daniele, Armenio, Miriam, Arcangeli, Annarosa, Castiglione, Francesca, Messerini, Luca, Di Costanzo, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681220/ https://www.ncbi.nlm.nih.gov/pubmed/33240421 http://dx.doi.org/10.3892/ol.2020.12276 |
Ejemplares similares
-
hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy
por: Muratori, Leonardo, et al.
Publicado: (2016) -
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas
por: Iorio, Jessica, et al.
Publicado: (2022) -
Evaluation of RAS Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
por: Lastraioli, Elena, et al.
Publicado: (2023) -
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients()
por: Iorio, Jessica, et al.
Publicado: (2020) -
A Transcriptomic Approach Reveals Selective Ribosomal Remodelling in the Tumour Versus the Stromal Compartment of Metastatic Colorectal Cancer
por: Lastraioli, Elena, et al.
Publicado: (2021)